Quotient Sciences Recognized as a Winner of 2025 CDMO Leadership Awards
Read More31 - 35 of 154 results
In a recent article with Pharm Tech discussing how advancements in technology and a more patient-centric focus are pushing drug formulation development into exciting new directions, Asma Patel, VP, Integrated Development Services at Quotien...
Learn more
In this article by International Biopharmaceutical Industry, Martin Wing-King, VP and General Manager, Site Head at our Reading facility, explores the demand for accelerated first-in-human trials and outlines how simple formulations can be ...
Learn more
Quotient Sciences is pleased to announce that its Chief Scientific Officer, Dr. Andy Lewis, has joined the scientific advisory board for a new journal by the Royal Society of Chemistry – RSC Pharmaceutics.
Learn more
NOTTINGHAM, UK, ENCINITAS, CA; September 10, 2024 – VS-041, a novel and potentially life-saving treatment for heart failure, developed by Vasa Therapeutics, a San Diego-based biotechnology company, has reached a major clinical milestone wit...
Learn moreIn this article by Pharma Focus, Dr. Andrew Lewis, the Chief Scientific Officer at Quotient Sciences discusses the efficiency of oral peptides and their attractiveness as a drug candidate. "Continued advancements in drug deliv...
Learn more
